OCULAR THERAPEUTIX, INC
OCULAR THERAPEUTIX, INC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 2, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 27.2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 26 concluded trials, 92% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 2, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| January 8, 2027 | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | Trial Milestone | Phase 3 |
| March 15, 2027 | A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy | Trial Milestone | Phase 3 |
| August 1, 2030 | Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study | Trial Milestone | Phase 3 |
Track OCUL alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open OCUL in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.